Preclinical data consistently show neuroprotective effects, though the dedicated EVOKE trial of semaglutide for Alzheimer's disease found no significant benefit
Healthy weight loss happens gradually, with most patients aiming for a loss of one to two pounds per week
Obesity an indication for GLP-1 treatment
Grosso G, Laudisio D, Frias-Toral E, Barrea L, Muscogiuri G, Savastano S, et al
GLP-1 medications profoundly alter appetite and food preferences
To determine if your Medicaid plan covers Ozempic, refer to the plans drug formulary or contact your states Medicaid agency